Mersana Therapeutics, Inc. MRSN
At closeJan 6, 2026, 4:00 PM EST
After hours · Jan 6, 4:00 PM ET
52-week range unavailable
- YTD
- +0.52%
- 1 year
- -14.47%
- Market cap
- 145.36M
- Revenue (ttm)
- 34.84M
- Profit margin
- -214.20%
- Shares out
- 123.53M
- Forward P/E
- -2.19
- YTD return
- +0.52%
- 1-year return
- -14.47%
- Volume
- 624.02K
- Open
- 28.78
- Previous close
- 29.08
- Day's range
- 28.78 – 29.08
- Analysts
- Strong Buy
- Price target
- 6.50 (-77.6%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 5.43
- Price / book
- 5.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 63.70%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Short % of float
- 9.30%
- 50-day average
- 2.16
- 200-day average
- 2.47
Analyst view
Consensus: strong buy
- Target (low)
- 3.00
- Target (mean)
- 6.50
- Target (high)
- 9.00
- Strong buy0
- Buy8
- Hold2
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.16455.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.18 | -0.09 | +0.09 | +50.00% |
| Aug 13, 2024 | Jun 1, 2024 | -0.18 | -0.20 | -0.02 | -11.11% |
| May 9, 2024 | Mar 1, 2024 | -0.18 | -0.16 | +0.02 | +11.11% |
| Feb 28, 2024 | Dec 1, 2023 | -0.20 | -0.16 | +0.04 | +20.00% |
| Nov 7, 2023 | Sep 1, 2023 | -0.31 | -0.35 | -0.04 | -12.90% |
| Aug 8, 2023 | Jun 1, 2023 | -0.39 | -0.47 | -0.08 | -20.51% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 27, 2024 | Citigroup | main | Buy | Buy |
| Aug 14, 2024 | Baird | main | Neutral | Neutral |
| Mar 19, 2024 | JP Morgan | up | Underweight | Neutral |
| Feb 29, 2024 | Wedbush | up | Neutral | Outperform |
| Feb 29, 2024 | Truist Securities | up | Hold | Buy |
| Feb 29, 2024 | Baird | main | Neutral | Neutral |
About Mersana Therapeutics, Inc.
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- mersana.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on MRSN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BALA MOHAN | Officer | Sale | Oct 27, 2024 | 54,731 |
| CARVAJAL ALEJANDRA V. | Officer | Sale | Oct 2, 2024 | 63,716 |
| DERE WILLARD H | Director | Stock Award(Grant) | Jan 1, 2024 | 39,182 |
| DESCHUYTNER BRIAN | Chief Operating Officer | Sale | Oct 2, 2024 | 94,824 |
| HUBER MARTIN H JR | Chief Executive Officer | Sale | Sep 11, 2024 | 116,327 |
| LOWINGER TIMOTHY B | Chief Technology Officer | Sale | Oct 2, 2024 | 235,642 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 15.68% | 19,364,688 | 29.63M | Sep 29, 2024 |
| Nextech Invest Ag | 9.77% | 12,067,246 | 18.46M | Sep 29, 2024 |
| VR Adviser, LLC | 9.17% | 11,328,000 | 17.33M | Sep 29, 2024 |
| Bain Capital Life Sciences Investors, LLC | 7.01% | 8,663,673 | 13.26M | Sep 29, 2024 |
| Blackrock Inc. | 6.98% | 8,621,861 | 13.19M | Sep 29, 2024 |
| Vanguard Group Inc | 5.81% | 7,177,458 | 10.98M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.81% | 3,470,892 | 5.31M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.40% | 2,966,700 | 4.54M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.23% | 1,524,973 | 2.33M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.96% | 1,179,839 | 1.81M | Aug 30, 2024 |
| Vanguard Explorer Fund, Inc. | 0.50% | 614,971 | 940.90K | Jul 30, 2024 |
| Fidelity Extended Market Index Fund | 0.44% | 538,996 | 824.66K | Oct 30, 2024 |